Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
American journal of hematology
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab alone (NCT01471210) or combined with rituximab (NCT01775631). Sixty patients received urelumab (0.3 mg/kg IV Q3W, 8 mg IV Q3W, or 8 mg IV Q6W); 46 received urelumab (0.1 mg/kg, 0.3 mg/kg, or 8 mg IV Q3W) plus rituximab 375 mg/m
Earle A. Chiles Research Institute
Timmerman, John; Herbaux, Charles; Ribrag, Vincent; Zelenetz, Andrew D; Houot, Roch; Neelapu, Sattva S; Logan, Theodore; Lossos, Izidore S; Urba, Walter; Salles, Gilles; Ramchandren, Radhakrishnan; Jacobson, Caron; Godwin, John; Carpio, Cecilia; Lathers, Deanne; Liu, Yali; Neely, Jaclyn; Suryawanshi, Satyendra; Koguchi, Yoshinobu; and Levy, Ronald, "Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma." (2020). Articles, Abstracts, and Reports. 2868.